These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9705597)

  • 1. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
    Rutgeerts P
    Mediators Inflamm; 1998; 7(3):137-40. PubMed ID: 9705597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budesonide modified-release capsules.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
    Gross V
    Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
    Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
    Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide for Crohn's disease.
    Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide in inflammatory bowel disease.
    Lamers CB; Wagtmans MJ; van der Sluys Veer A; van Hogezand RA; Griffioen G
    Neth J Med; 1996 Feb; 48(2):60-3. PubMed ID: 8819801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Local or systemic treatment of inflammatory bowel diseases?].
    Schmassmann A; Halter F
    Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection].
    Vermeire S; Rutgeerts P
    Zentralbl Chir; 1998; 123(4):352-6. PubMed ID: 9622893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of topically and systemically active steroids on circulating leukocytes in Crohn's disease.
    Tillinger W; Gasche C; Reinisch W; Lichtenberger C; Bakos S; Dejaco C; Moser G; Vogelsang H; Gangl A; Lochs H
    Am J Gastroenterol; 1998 Oct; 93(10):1848-53. PubMed ID: 9772043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Z Gastroenterol; 1995 May; 33(5):247-50. PubMed ID: 7610691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide in the treatment of inflammatory bowel disease.
    Silverman J; Otley A
    Expert Rev Clin Immunol; 2011 Jul; 7(4):419-28. PubMed ID: 21790284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroid-sparing treatments in patients with Crohn's disease.
    Plevy SE
    Am J Gastroenterol; 2002 Jul; 97(7):1607-17. PubMed ID: 12135008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
    Lichtenstein GR; Bengtsson B; Hapten-White L; Rutgeerts P
    Aliment Pharmacol Ther; 2009 Mar; 29(6):643-53. PubMed ID: 19035972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
    Sandborn WJ; Feagan BG; Lichtenstein GR
    Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
    de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
    Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence of Crohn's disease in the neoterminal ileum after ileal resection: is prevention therapy possible?
    Rutgeerts P
    Neth J Med; 1994 Aug; 45(2):60-4. PubMed ID: 7936007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.